Compare NWTG & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | CLGN |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.2M |
| IPO Year | 2022 | 2015 |
| Metric | NWTG | CLGN |
|---|---|---|
| Price | $1.27 | $3.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 32.7K | ★ 9.4M |
| Earning Date | 05-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,135,000.00 | N/A |
| Revenue This Year | $53.21 | $240.45 |
| Revenue Next Year | $40.00 | $38.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 136.14 | N/A |
| 52 Week Low | $0.70 | $0.26 |
| 52 Week High | $2.07 | $3.18 |
| Indicator | NWTG | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.23 | 52.42 |
| Support Level | $0.97 | $0.30 |
| Resistance Level | $1.44 | $0.43 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 35.29 | 10.90 |
Newton Golf Co Inc is a technology-forward golf company engaged in designing, manufacturing, and selling performance golf equipment, including premium golf shafts and putters, and focuses on developing technology-driven golf products intended to enhance player performance. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.